An Overview of Japan’s Bioeconomy Strategy
and Greater Tokyo Biocommunity

Prof. Yoshiaki Tsukamoto
Executive Director, Japan Bioindustry Association(Secretary General, Greater Tokyo Biocommunity)

Japan’s Bioeconomy Strategy

Global Trends in the Bioeconomy

OECD : “The Bioeconomy to 2030” (2009)• The global biotechnology market is expected to reachapproximately 1.6 trillion USD by 2030 （Industrial : 39%,Agriculture: 36%, Health: 25%.）49 countries havedeveloped strategies
related to the bioeconomy.

EU：“Innovation for Sustainable Growth:
A Bioeconomy for Europe” (2012)
US：“National Bioeconomy Blueprint” (2012)
JAPAN: The Bioeconomy Strategy (2019)

Ref：METI Subcommittee on
Biotechnology of committee on Commerce,
Distribution and Information

3

Japan’s Bioeconomy Strategy
Realizing “World’s Most Advanced Bioeconomy” Society by 2030
Expansion of market
Target: A total market size of $840 billion in 2030 from current $550 billion

Formation of biocommunity
Building value chains in each market area by creating diverse andunique communities across Japan and by supporting theircontinued growth.

Promotion of data linkage
Creating an environment that allows for broad and flexible collaboration,
including in different fields.
4

Expansion of Bio-Based Market
Aiming for a total market size of US$840 billion in 2030
White-Bio

Bio-manufacturing
Engineering biology-based
biofoundry & biorefinery
R&D support for bioplastics$295 Bil. (2018) → $485 Bil.

Healthcare
Target setting for eachmarket area
Formulation of initiatives
by backcasting

Plant-based
car materials(Biomaterials,Bioplastics,Biofoundry<Industry & foodproduction>)Biopharmaceuticals (incl.
vaccines) development &production
Large-scale genome database$240 Bil. (2018) → $330 Bil.

Biodegradableplastics

Primary production

Innovational drugs Digital healthGreen-Bio

Automated agriculture, employmentof latest genome editing
technology-based breedingLarge wooden architecture design
Safe, sound and& construction$7.3 Bil. (2018) → $25 Bil.

Red-Biohighly functional
food(Biopharmaceutical,regenerative
medicine, cell/genetherapy, etc.)
Woodenskyscraper(Sustainable primaryproduction system &smart forestry)5

Japan’s Leading Biocommunity
 Form an organic network with regional centers, with the international center at the core.
 Activate distinctive bio-industries throughout the country and promote the accumulationof excellent human resources and investment from Japan and abroad while also
connecting with global clusters.
Tsuruoka Science Park,Keio Univ., Tsuruoka City,
Spiber Inc. etc…

Hokkaido Prime

Hokkaido Univ.,
Hokkaido Government,
NOASTEC etc…

Nagaoka City, Nagaoka Univ. of Tech.,Natl. Inst. of Tech. Nagaoka College,
JA etc…

Tsuruoka

Kyoto Univ., iPS Res. Inst.,
RIKEN, Osaka Univ.,
Kobe Univ., KinkiBio etc…
Fukuoka Pref., Kurume City,
Kyushu Univ., Kurume Univ.,
BONAC corporation etc…

OIST, Meisho Univ., Ryukyu
Univ., Natl. Inst. of Tech
Okinawa College, Okinawa
General Bureau etc…

Nagaoka

Global

Biocommunity
Kansai (BiocK)

Fukuoka

Okinawa

Greater Tokyo Biocommunity (GTB)
Hiroshima Bio DX
Hiroshima Pref., Higashi-Hiroshima
City, Hiroshima Univ., Hiroshima
LOVE it Consortium etc…

Global biocommunity with comparable
size to the world bioclusters
Biocommunity with regional
characteristics

6

Promotion of Data Linkage
 Establish an environment for data linkage based on the governmental common measures

Soil Condition Data

Bio-manufacturing Supportive
Data

Smart Breeding Data

Food/Health/Microbiome
Information

Genome Data

Biological data linkage
Develop and enrich the data platform for R&D projects＋ Provide guidelines for data linkage and usage（by the end of FY2022)
Infrastructure for datalinkage in each field

SmartCity

MedicalAgriculture

Bio

Cross-disciplinary platform

Governmental Data StrategyOthers• Prepare tool (API, data catalogues), coordinate rules• Coordinate repository, etc.

7Greater Tokyo Biocommunity(GTB)Potential of Tokyo Area (1)IPs & Publications
The Top 100 Science & Technology Clusters 2022 (only Top 10 were shown）
Country

Share of total PCT*1filings (%)

Share of total*2publications (%)

Total (%)

Japan

10.7

1.6

12.3

China/Hong Kong

8.2

1.9

10.1

3 Beijing

China

2.8

3.7

6.5

4 SeoulKorea

4.0

1.8

5.8

US

3.7

0.8

4.6

6 Shanghai-Suzhou

China

2.0

2.1

4.1

7 Osaka-Kobe-Kyoto

Japan

3.0

0.7

3.7

8 Boston-Cambridge

US

1.4

1.0

2.4

9 New York City

US

1.1

1.0

2.2

France

1.2

0.9

2.1

Rank

Cluster

1 Tokyo-Yokohama
2 Shenzhen-Hong Kong-Guangzhou

5 San Jose-San Francisco

10 Paris*1. Inventors listed in patent applications under WIPO’s Patent Cooperation Treaty (PCT), spanning years 2016 to 2020
*2. Authors listed in scientific publications in the Web of Science’s Science Citation Index Expanded (SCIE) and covering the same period.
From WIPO “Global Innovation Index 2022”
9

Potential of Tokyo Area (2)Number of Drug Pipelines in Development2

Bio-related drug pipelines in the developmental stages from preclinical to Phase III were counted (as of the end of 2021).

Data searched with BioMedTracker and “Asu-no-sinyaku” by Deloitte Tohmatsu

10

GTB Bio-innovation Promotion Areas
5. Kawasaki Area

3. HOTS HILL Area

The Open Innovation City with
Direct Access to Haneda Airport

6. Yokohama Area

TheLargest
Concentration ofAcademiain GTB

4. Nihonbashi Area

The Biggest
Science Citywith VariousInstitutions

Global LifeScience
Bbusiness
Hub in theHeart ofTokyo

湯島

From brochure

From LINK-J HP

From Press Release1

Innovative City Focusing on
Health and Medical Care

2
Tokyo Industrial University

Yokohama City University

3 4

BioJapan

7. Shonan Area
An Innovation Hub with the Largest
Wet Lab, in Collaboration with
Neighbouring
Hospitals

Shonan Health Innovation Park8567

1. Tsukuba Area

8Note 1) In addition to areas above, Shinjuku, Shinanomachi,Waseda, Tsukiji, Daiba, Tokorozawa, and Wako areemerging areas.
Note 2) As new areas are developed, area definition may
be restructured.

2. Kashiwanoha Area
The Smart
City withTop-Tier
Universities
and theNational
CancerCenterTodai
Kashiwa
CampusNational
CancerCenterChiba
Kashiwanoha
CampusFrom Kashiwanoha Smart CityHP

8. Chiba/Kazusa Area
TheResearchBase ofPlant andImmunological
MedicareKazusaDNA Lab

Chiba
University11

Structure of GTB Council
GTB council
Chair: Mr. Osamu Nagayama (President, JBA)
Vice-Chair:Mr. Manabu Miyasaka (Vice-Governor of Tokyo
Metropolitan Government) Mr. Nagayama Mr. Miyasaka Dr. Watanabe
Dr. Toshiya Watanabe (Vice-President, Univ. of Tokyo)
Industries
Related organizations

Academia• Established in 2021
• Three chairs are frombusiness, academia andgovernment.

Advisor

Local governments

Financial & investment institutions

Observer(Government)
Collaborations

GTB supporter

GTB practicalmember meeting
Working group
GTB secretariat(Japan Bioindustry Association)

In operating the GTB Council, participants will be
convened at the working level to discuss
operational policies and specific initiatives in apractical manner.
Members were selected from the GTB Council organizations
to discuss detailed agenda items in each area, including
specific actions to be taken. Established as needed.

Secretary General:
Mr. Yoshiaki Tsukamoto(Executive Director, JBA)

Miscellaneous
Regional
biocommunities,
The Tokyo
Consortium - Startup
Ecosystem,
COI-NEXT “Tsukuba
Digital-BioInternational Center”
etc.

12

GTB: Goal and Approaches
Goal

Make the Tokyo Area one of world’s premier innovation centers

Value chain
AcademiaApproaches

Biotech startup

Innovation/Invention

RealizationResearchcollaboration

Startupdevelopment

Pharma/Chemicalcompany

Commercialization/
Production

Socialimplementation/
Development ofindustry &regional area

Investment to manufacturing
facilities

Infrastructure (network, human resource, coordination of innovation hubs, etc.)
International recognition, Foreign investment
13What GTB aims for: KPI
Main KPI: Market Expansion

Supplemental KPI (1): Investment to biotech startups$ 3.2 bil.

$ 940bil.
2020

CAGR:
3.6%

$ 1,340bil.
2030

Market : Total of annual sales of the companies in Tokyo
area with the membership of 5 bio-related associations1)

Estimated foreign
investment:$18-27 mil.

Foreign($1.6 bil.) Investment
DomesticInvestment$ 0.27 bil.
20202030

Supplemental KPI (2): Research collaboration & Ranking
 Number of new large collaborative research projects adopted:
5 to 10 per year (2030)
 Startup Genome’s Startup Ecosystem Ranking (Life ScienceSector): within the 5th prize (2030) from the 25th prize (2021)

1): Japan Bioindustry Association, Japan
Pharmaceutical Manufacturers Association, Forumfor Innovative Regenerative Medicine, SAMURAI
Biotech Association, Japan Association forTechno-innovation in Agriculture, Forestry &Fishery
Annual sales are based on the available
information on most recent full year results of eachcompany (as of January, 2022)

14

Recent Typical Progress$2.1 Bil. of governmental
investment for manufacturing
facilities of biopharmaceuticals
Subsidy for the development of biopharmaceuticalproduction sites to strengthen the vaccine
production system:
Sites determined at the end of September

20 research collaboration projects
started in GTB and Kansai Areas
National projects in GTB:
Tsukuba Digital Bio International Center (JST),
Wellbeing Healthcommons Collaboration Hubs (JST),
Bioeconomy Innovation Hub to Realize Carbon
Cycle Society (JST), Biomanufacturing (NEDO),
Smartcell industry (NEDO), Industrialization of
medical device (AMED), Next-generation nucleic
acid medicine (AMED)$450 Mil. of governmental investment
for Japanese pharmaceutical startup
companies
Governmental accreditation of and subsidy for venture
capitals to support innovative pharmaceutical startups

Tools for sharing activities of participating organizations
GTB website

Twitter

https://note.com/gtb_com/m/m5447989128fd

https://twitter.com/TokyoGreater

1616

See you next time at BioJapan 2023 !

October 11 Wed. -13 Fri., 2023
Pacifico Yokohama

Contact: BioJapan Secretariat Officec/o JTB Communication Design

E-mail: biojapan@jtbcom.co.jp

Tel: +81-3-5657-0758

Web: www.ics-expo.jp/biojapan/